Covid-19 vaccines reduce the chances of developing severe infection and mortality, ICMRChief Balram Bhargava said on Tuesday.
Responding to a question about people contracting the coronavirus infection even after taking both doses of COVID vaccine, he said these are "disease-modifying" vaccines and there is an 85 percent reduction in hospitalisation after vaccination which is well established internationally.
"These vaccines are disease-modifying. After two doses are administered, the antibodies develop.The COVID-19 vaccines reduce the chances of developing severe infection and death due to the disease," the ICMR Director General said.
The Indian Council of Medical Research (ICMR) is the country's apex health research body.
Currently, two vaccines -- Covaxin by Bharat Biotech and Oxford-AstraZeneca's Covishield manufactured by Serum Institute of India (SII) -- are being used for inoculation in India.
India's drug regulator has also granted permission for the restricted emergency use of the Russian COVID-19 vaccine Sputnik V with certain conditions.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)